texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Austin Central Research & Clinical Trials

Austin Central participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin Central

Biliary Cancer

STAR INCB054828 in Cholangiocarcinoma

A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) Read More

Phase: II

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Bladder Cancer

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) Read More

Phase: II

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) Read More

Phase: II

Breast Cancer

Ph3 Abemaciclib HR+ HER2- (monarchE)

(I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer Read More

Phase: III

STAR Open Label VT-464 Adv Breast Cancer

A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006) Read More

Phase: II

Ph 3 Pembro Neoadj TNBC

A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 Read More

Phase: III

Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304) Read More

Phase: III

Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304) Read More

Phase: III

Adj Therapy Node+orHRNode-3-Inv TNBC

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) Read More

Phase: III

Ph1b/2 Eribulin+Pembro mTNBC

ENHANCE 1: An Open-Label, Single-Arm Multicenter Phase 1b/2 Study toEvaluate the Efficacy and Safety of Eribulin Mesylate inCombination With Pembrolizumab in Subjects With MetastaticTriple-Negative Breast Cancer (mTNBC) (E7389-M001-218) Read More

Phase: II

MRI evaluation of breast tumor growth and treatment response

STAR Cape/tras +/- ONT-380 HER2+ mBC

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206) Read More

Phase: II

Carcinoid

STAR Ph2 Pembro Recurr/Meta Cut. SCC

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) Read More

Phase: II

Cervical Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Ph3 REGN2810 Plat-Refract Cervical

An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator''s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma (R2810-ONC-1676) Read More

Phase: III

Colon Cancer

Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC

CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) Read More

Phase: III

Endometrial Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Fallopian Tube Cancer

PacCarboBev +/-Atezo, 1L Ovrn IMagyn050

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523 Read More

Phase: III

Gastric Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Head and Neck Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Hematologic

Ph3 HR MDS, CMML, AML

Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Read More

Phase: III

Leukemia

Ublituximab+TGR-1202 Cross-over

(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More

Phase: II

informCLL™ Registry

informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) Read More

Phase: IV

Ph3 HR MDS, CMML, AML

Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Read More

Phase: III

Liver Cancer

PhIb/II BBI608/503+Sorafenib HCC

A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103) Read More

Phase: I/II

Lung Cancer

Ph2 MGCDs+Nivo NSCLC

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500) Read More

Phase: II

Ph3 Etopo-Cisp/Carb +/- Pembro 1L SCLC

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer (Keynote-604) Read More

Phase: III

Tepotinib stage IIIB/IV NSCLC w/ METex14

A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations(VISION) Read More

Phase: II

Ph2 adv/ mNSCLC (B-FAST)

A PHASE II/III MULTICENTER STUDYEVALUATING THE EFFICACY AND SAFETY OFMULTIPLE TARGETED THERAPIES ASTREATMENTS FOR PATIENTS WITH ADVANCEDOR METASTATIC NONƒ{SMALL CELL LUNGCANCER (NSCLC) HARBORING ACTIONABLESOMATIC MUTATIONS DETECTED IN BLOOD(B-FAST: BLOOD-FIRST ASSAY SCREENINGTRIAL)- BO29554 Read More

Phase: II/III

Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC

CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Read More

Phase: III/IV

Ph3 Nivo vs Plat-Doublet chemo NSCLC

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816) Read More

Phase: III

Lymphomas

Ph3 Polatuzumab 1L DLBCL [POLARIX]

(GO39942): A PHASE III, MULTICENTER, RANDOMIZED,DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA Read More

Phase: III

STAR CC-122+Rtx, FL R/R to Len

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) Read More

Phase: I

Ph2 R/R MCL (CITADEL-205)

A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205 Read More

Phase: II

TGR-1202 +/- Ublituximab in NHL

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205) Read More

Phase: II

Rev+Ritux, R/R FL, MZL, MCL (MAGNIFY)

A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) Read More

Phase: III

STAR Brentux in older pts w/HL 1L

SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above Read More

Phase: II

Melanoma

Ph3 Cobi + Atezo vs Pembro BRAF Melanoma

A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722) Read More

Phase: III

Mesothelioma

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Multiple

Genetic Risk Evaluations in High Risk Cancer Populations

Myelodysplastic Syndrome

Ph3 HR MDS, CMML, AML

Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Read More

Phase: III

Myelofibrosis

STAR Ph2 Itacitinib +/- Ruxo in MF

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Read More

Phase: II

Myelomas

Observational INSIGHT MM study

A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) Read More

Phase: IV

Ph4 Ixazomib+Lena & Dex MM (MM-6)

C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen Read More

Phase: IV

Neuroendocrine Tumors

STAR BSC +/- LAN in Lung NETs [SPINET]

A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 Read More

Phase: III

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Ovarian Cancer

Ph2 NUC-1031 Pt-Resist Ovarian

A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105) Read More

Phase: II

PacCarboBev +/-Atezo, 1L Ovrn IMagyn050

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523 Read More

Phase: III

Niraparib HRD+ Adv Ovrn post 1L [PRIMA]

PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) Read More

Phase: III

Pancreatic Cancer

Erlotinib + ChemoRad Pancreas Adeno

A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848) Read More

Phase: III

FOLFOX +/1 AM0010 Panc

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301) Read More

Phase: III

Penile Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Peritoneal Cancer

PacCarboBev +/-Atezo, 1L Ovrn IMagyn050

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523 Read More

Phase: III

Prostate Cancer

Ph3 aPDL1/Atezo+Enza mCRPC

A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385 Read More

Phase: III

STAR Ph2 Rucaparib mCRPC (TRITON 2)

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 Read More

Phase: II

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

Rectal Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC

CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) Read More

Phase: III

Renal Cancer

Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER) Read More

Phase: III

Ph3 Pembro RCC post nephrectomy

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) Read More

Phase: III

Skin Cancer

STAR Ph2 Pembro Recurr/Meta Cut. SCC

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) Read More

Phase: II

Solid Tumors

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Testicular Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Thymomas

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Thyroid Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Urothelial Cancer

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) Read More

Phase: II

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) Read More

Phase: II

Uterine Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Vaginal Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II